Idebenone Treatment of Early Parkinson's Diseasesymptoms

This clinical trail was a multicenter, parallel, randomized, double‐blind, placebo‐controlled study led by Professor Liu Chunfeng from the Second Affiliated Hospital of Suzhou University which consisted of 15 sub‐centers with a total of 180 subjects. This clinical study is divided into two phases: The first stage: double‐blind period, 24 weeks. Three queues containing idebenone 180 mg/d,360 mg/d and placebo. The second stage: open label extension period, 24 weeks. All enrolled participants continued to take idebenone 180 mg/d to study the long‐term effects of idebenone.